Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for diagnosing esophageal squamous carcinoma and detection kit

A biomarker, esophageal squamous cell carcinoma technology, applied in the field of medicine and biology, can solve the problems of poor prognosis, limited treatment methods, and 5-year survival rate of less than 20%, and achieve good diagnostic and differentiation effects

Active Publication Date: 2022-03-11
ZHENGZHOU UNIV
View PDF24 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, because the current treatment methods for ESCC are very limited, the prognosis of patients is poor, and the overall 5-year survival rate is less than 20%.
[0004] At present, there are relatively few studies on autoantibodies that can be used for the diagnosis of esophageal squamous cell carcinoma. Serological autoantibody markers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for diagnosing esophageal squamous carcinoma and detection kit
  • Biomarker for diagnosing esophageal squamous carcinoma and detection kit
  • Biomarker for diagnosing esophageal squamous carcinoma and detection kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1: Using human proteome chips to screen markers for the diagnosis of esophageal squamous cell carcinoma

[0039] 1. Experimental sample:

[0040] The sera of 30 patients with esophageal squamous cell carcinoma (esophageal squamous cell carcinoma group) and 24 normal subjects (normal control group) were collected from the specimen bank of the Henan Provincial Key Laboratory of Cancer Epidemiology; among them, the serum of 30 patients with esophageal squamous cell carcinoma Patients with esophageal squamous cell carcinoma confirmed by pathology without any treatment; 24 normal human serums were obtained from healthy subjects, and the inclusion criteria for healthy subjects were: no cardiovascular, respiratory, liver, kidney, gastrointestinal tract , endocrine, blood, mental, or nervous system diseases and the history of the above diseases, no acute or chronic diseases, no autoimmune diseases, no evidence of any tumor-related; moreover, 30 patients with esophageal ...

Embodiment 2

[0060] Example 2: ELISA detection of serum expression levels of anti-tumor-associated antigens ZPR1, HSF1, MAGEA4, HDAC1 autoantibodies

[0061] The expression levels of the four anti-tumor-associated antigen autoantibodies screened in Example 1 in human serum were detected by enzyme-linked immunosorbent assay (ELISA).

[0062] 1. Experimental sample:

[0063] The samples of 229 patients with esophageal squamous cell carcinoma (esophageal squamous cell carcinoma group) and 229 normal controls (normal control group) included in this study were all obtained from the specimen bank of the Key Laboratory of Cancer Epidemiology in Henan Province; among them, 229 patients with esophageal squamous cell carcinoma Serum from patients with esophageal squamous cell carcinoma confirmed by pathology without any treatment; 229 normal human serum from healthy subjects, the inclusion criteria of healthy subjects are: no cardiovascular, respiratory, liver, kidney , gastrointestinal tract, endo...

Embodiment 3

[0098] Example 3: Assessment of the ability of 4 autoantibodies against tumor-associated antigens to diagnose esophageal squamous cell carcinoma

[0099] 1. Experimental sample:

[0100] The serum of 229 patients with esophageal squamous cell carcinoma and the serum of 229 normal controls included in Example 2 are randomly divided into a training set and a verification set in a ratio of 7:3; 161 patients with esophageal squamous cell carcinoma (referred to as esophageal squamous cell carcinoma) in the training set 161 cases of normal control serum (denoted as normal control group); 68 cases of serum from esophageal squamous cell carcinoma patients and 68 cases of normal control serum in the validation set. Then according to the results of the expression levels of anti-tumor-associated antigens ZPR1, HSF1, MAGEA4, and HDAC1 autoantibodies in the training set and verification set detected by ELISA in Example 2, GraphPad Prism8.0 was used to draw ROC curves to analyze the four an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medical biology, and particularly discloses a biomarker for auxiliary diagnosis of esophageal squamous carcinoma and a detection kit. The biomarker for auxiliary diagnosis of esophageal squamous cell carcinoma provided by the invention is at least one of autoantibodies of anti-tumor related antigens ZPR1, HSF1, MAGEA4 and HDAC1, the expression level of the marker in serum of a patient with esophageal squamous cell carcinoma is higher than that of a normal person, and the difference has statistical significance. The invention also provides a kit for auxiliary diagnosis of esophageal squamous carcinoma, the kit contains a reagent for detecting the marker, and the reagent is used for detecting the biomarker in a sample through enzyme-linked immunosorbent assay, a protein chip, immunoblotting or microfluidic immunoassay. By detecting the expression level of the biomarker in human serum, esophageal squamous cell carcinoma patients and normal people can be effectively distinguished, and the marker can be used for esophageal squamous cell carcinoma diagnosis.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and specifically discloses a biomarker and a detection kit for diagnosing esophageal squamous cell carcinoma. Background technique [0002] Esophageal cancer is the sixth leading cause of cancer death in the world, and the incidence and mortality of esophageal cancer in China rank first in the world. Global cancer epidemiological statistics show that in 2020, there will be 604,000 new cases of esophageal cancer in the world, and 544,000 people will die from esophageal cancer. The death rate of esophageal cancer ranks sixth among malignant tumors. The pathological types of esophageal cancer mainly include squamous cell carcinoma and adenocarcinoma, 90% of which are esophageal squamous cell carcinoma (also known as esophageal squamous cell carcinoma, ESCC). Since the early symptoms are not specific and easy to be ignored, most ESCC patients are already in the middle and advanced stage...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/543
CPCG01N33/57407G01N33/57488G01N33/543
Inventor 王鹏孙桂英叶华陈慧丽史健翔代丽萍王科妍
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com